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We aimed to determine the value of the paired-pulse inhibition (PPI) in the auditory cortex in patients with Parkinson’s disease
(PD) and analyze its dependence on clinical characteristics of the patients. The central (Cz) auditory evoked potentials were
recorded in 58 patients with PD and 22 age-matched healthy subjects. PPI of the N1/P2 component was signiﬁcantly (P<. 001)
reduced for interstimulus intervals 500, 700, and 900ms in patients with PD compared to control subjects. The value of PPI
correlated negatively with the age of the PD patients (P<. 05), age of disease onset (P<. 05), body bradykinesia score (P<. 01),
and positively with the Mini Mental State Examination (MMSE) cognitive score (P<. 01). Negative correlation between value
of PPI and the age of the healthy subjects (P<. 05) was also observed. Thus, results show that cortical inhibitory processes are
deﬁcient in PD patients and that the brain’s ability to carry out the postexcitatory inhibition is age-dependent.
1.Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder
primarily related to pathology in the substantia nigra
pars compacta dopaminergic neurons that results in the
development of thebraindopamine deﬁcit.The mechanisms
and pathophysiology of this disease are not completely
understood [1]. Although the cardinal features of the disease
are movement disorders (rigidity, tremor, bradykinesia), the
manifestations of PD also comprise a variety of diverse
abnormalities including disturbance of sensory gating and
cognitive decline [2–4].
It has been previously reported that disorders in PD
largely occur due to the imbalance of inhibitory and excita-
tory processes in cortical and subcortical neuronal circuits
[5–10]. A paired-pulse paradigm is usually used to study
postexcitatory inhibition eﬀect related to sensory gating
mechanisms and synaptic processes in neurotransmitters
release [11, 12]. There are two mechanisms that might
explain paired-pulse inhibition (PPI) phenomena. The ﬁrst
mechanism is the decrease in release probability of excitatory
neurotransmitters from terminals of aﬀerent axons [13–15].
This eﬀect is likely the result of an inhibition of calcium
inﬂux through presynaptic receptors which play a causal
role in the release of glutamate from synaptic vesicles on
aﬀerentstimulation[16].Anotherpossiblemechanismofthe
decrement of the second response on paired stimulation is
connected with synaptically released GABA from terminals
of inhibitory interneurons [17–19]. As the paired-pulse
facilitation, PPI is considered to be a form of a short-term
synaptic plasticity [20, 21].
Several studies demonstrated a decreased postexcita-
tory inhibition of the midlatency (P 49) auditory evoked
responses and median nerve somatosensory evoked poten-
tials (P13-N18, P24-N31, P44-N75) on paired stimulation in
patients with PD compared to healthy age-matched people
[22, 23]. In the work of Perriol et al., the authors revealed
a pronounced reduction of the prepulse inhibition of the
N1/P2 component of auditory evoked potentials in PD and
dementia with Lewy bodies [24]. In our previous study,2 Parkinson’s Disease
we showed reduction of the postexcitatory inhibition of the
N1/P2 complex in the auditory cortex in patients with PD
and positive eﬀect of Levodopa administration on its value
[25].
The aim of this study was to analyze the dependence
of the PPI value of the N1/P2 component of auditory
cortical evoked potentials on the clinical parameters of
the PD patients: age, sex, disease duration, age at disease
onset, Hoehn and Yahr stage, duration of the Levodopa
intake, Levodopa dosage, and indices of motor and cognitive
functions determined by using Uniﬁed Parkinson’s Disease
Rating Scale (UPDRS) and Mini Mental State Examination
(MMSE).
2.SubjectsandMethods
2.1. Subjects and Study Conditions. Studies were performed
in two groups. The ﬁrst group included 58 PD patients, with
the severity of the disease corresponding to 1.5–3.0 of Hoehn
and Yahr [26] scale (28 men and 30 women, mean ± SE age
61.5±1.1, range 45–74 years). The second group was control
and had 22 age-matched healthy subjects (10 men and 12
women, mean ± SE age 61.4 ± 1.2, range 48–73 years).
The study was approved in advance by the Ethical
Committee of the Institute of Gerontology and was in accor-
dance with the Helsinki declaration. The patients regularly
underwenttreatmentattheParkinson’sDiseaseCentreofthe
Institute of Gerontology and gave written informed consent
to participate in this study. The diagnosis of Parkinson’s
disease was determined according to the UK Bank Criteria
[27]. The patients had from 2 to 22 year individual histories
of idiopathic PD and were taking antiparkinsonian therapy
at individual doses of 187.5–700mg of Levodopa/Carbidopa
daily. Besides Levodopa/Carbidopa, the patients were using
other antiparkinsonian medication: Selegiline, Pramipexol,
and Amantadine. The neurological status of PD patients
was evaluated with UPDRS [28, 29] in the ON state one
hour after Levodopa/Carbidopa intake. MMSE was used
to study general cognitive status of the PD patients. The
53 (91%) individuals with PD did not show substantial
dysfunctions in memory, attention, or orientation and the
averaged value of the MMSE scores for whole group was
relatively high (27.9 ± 0.3). Only 5 (9%) subjects had scores
of 24 (i.e., a boundary index testifying to the doubtful signs
of cognitive dysfunction). Table 1 represents the details of
the PD patients’ evaluation.
Auditory evoked potentials were recorded in the PD
patients in their “OFF” state in the morning, after they were
free from Levodopa treatment and other antiparkinsonian
medications for at least 12 hours.
2.2. Recordings. The subjects were sitting comfortably in a
semireclined armchair in a quiet room with closed eyes.
Auditory evoked potentials were recorded at the vertex (Cz)
referenced to a linked-ear electrode. The ground electrode
was placed at the left wrist. The impedance of the electrodes
was less than 10kΩ. The electrode signal was ampliﬁed
using a band pass ﬁlter (0.53–30Hz), digitized with 200Hz
sampling rate, and stored for further analysis.
Table 1: Backgrounds of patients with Parkinson’s disease.
Total No of patients 58
Men 28
Women 30
Age, years (Mean ±SE) 61.5 ±1.1 (45–74)
Duration of illness, years
(Mean ±SE) 7.6 ±0.7 (2–22)
Hoehn and Yahr stage
(No of cases)
Stage 1.5 4
Stage 2.0 25
Stage 2.5 14
Stage 3.0 15
UPDRS scores (Mean ±SE) 58.6 ±2.2 (29–94)
MMSE scores (Mean ±SE) 27.9 ±0.3 (24–30)
Levodopa dosage
∗, mg/day
(Mean ±SE); 46 cases 359.2±23.3 (187.5–700)
Numerals in the parentheses represent data range. ∗The Levodopa
dosage in the table represents the dosage of Levodopa in Nacom
(250mg L-Dopa and 25mg L-Carbidopa).
The pattern for double stimulation consisted of paired
auditoryclickswith500,700,and900msinterstimulusinter-
vals (ISIs). The identical parameters (duration of 0.15ms
and intensity of 80dB HL-hearing level) were used for the
preceding conditioning click and following test click. Pairs
of clicks were delivered once every 7s for each ISI. Previous
studies have shown that stimulation at faster frequencies can
lead to a decrement in the cortical evoked potentials [30,
31]. A 2000–3000ms electroencephalography (EEG) epoch
was recorded for each trial, including a 300ms prestimulus
baseline. The recording time depended on ISIs. The epochs
contaminated with blinks or other artifacts were excluded
from the data and twenty acceptable artifact-free trials were
averaged for each ISI and used for further analysis.
2.3. Data Analysis. In EEG recordings to paired stimulation,
amplitudes of N1-P2 complex (peak to peak) in the ﬁrst
(A1) and the second (A2) responses were measured. The
amplitudes of the components N1 and P2 were estimated in
the 60–150ms and 120–220ms ranges of time, respectively.
The percent PPI of the N1-P2 complex was calculated using
the following formula: (A1 −A2)/A1∗100.
The results were analyzed statistically. Comparisons
between PD patients and control groups were made using
the nonparametric two-tailed Mann-Whitney criterion and
ANOVA statistics. The nonparametric Spearman test was
usedtoevaluatepossiblecorrelationbetweenthevalueofPPI
and characteristics of the investigated cohorts.
3. Results
3.1. Exploration of the Postexcitatory Inhibition upon Paired
Stimulation. ResultsshowedasigniﬁcantdiﬀerenceinPPIof
the N1/P2 component of auditory cortical evoked potentials
in two investigated groups. In PD patients, the postexcitatoryParkinson’s Disease 3
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Figure 1: Cortical auditory evoked potentials at paired-pulse stimulation with interstimulus intervals 700 and 900ms in the age-matched
healthysubjectandinthepatientwithParkinson’sdisease(PD).N1(I),P2(I)—thecomponentsofevokedpotentialsontheﬁrstconditional
and N1 (II), P2 (II)—on the second test stimuli. In the PD patient, the N1-P2 complexes appearing on second stimuli have greater
amplitudes,hencethepostexcitatoryinhibitionisreducedcomparedtocontrolsubject.Verticalsolidbarscorrespondtotheonsetofauditory
signals. Numerals in % represent value of paired-pulse inhibition calculated using the following formula: (A1 − A2)/A1∗100 where A1 and
A2 are amplitudes of the N1 (I)/ P2 (I) and N1 (II)/ P2 (II) components, respectively.
cortical inhibition was substantially reduced compared to
control subjects for ISIs 500, 700, and 900ms. Figure 1
demonstrates the native EEG recordings of the healthy age-
matched control and of the patient with Parkinson’s disease.
The recordings clearly illustrate greater amplitudes of N1-P2
complexes following the second stimulus of a pair in the PD
patient than in the control subject at ISIs of 700 and 900ms.
The mean values of PPI in the group of PD patients were
decreased to 29.8 ± 4.8% (P<. 01), 25.4 ± 3.2% (P<. 001),
and15.1±2.6% (P<. 001)forintervals500,700,and900ms,
respectively, as compared to these values (54.1±4.2%; 49.8±
2.3% and 42.9±2.7%) in the group of age-matched controls.
It was observed that the postexcitatory cortical inhibition
became statistically signiﬁcantly aﬀected on the stages of
PD corresponding to 1.5–2.0 of Hoehn and Yahr [26] scale.
Where PD was advanced, the reduction of inhibition was
expressed even stronger (Table 2). The mean amplitude of
N1-P2 complex elicited by a single (ﬁrst) auditory stimulus
in the group of PD patients was 16.2 ± 0.8mcVwhichwas
less than in age-matched subjects (18.5 ± 1.6mcV) but this
diﬀerence was not statistically signiﬁcant (P>. 05).
3.2. Correlation Study. Correlation analysis revealed negative
connection (P<. 05) between the averaged value of the
PPI (evaluated for ISIs of 500, 700 and 900ms) and age of
both healthy subjects (Figure 2) and PD patients (Table 3).
In the group of PD patients, the negative correlation (P<
.05) between the PPI value and the age at the onset of
the disease was also observed. It was further revealed that
the reduction of cortical inhibition negatively aﬀected the
cognitive functions: lower values of PPI corresponded to
decreased MMSE scores and vice versa. The degree of
PPI correlated positively with the summary MMSE score
(P<. 01) and with the score of attention plus memory4 Parkinson’s Disease
Table 2: Inhibition of the second N1-P2 complex of cortical auditory evoked potentials at paired-click stimulation in age-matched control
group and patients with Parkinson’s disease (Mean ±SE).
Study groups
Inhibition in % of the second N1-P2
Averaged complex at interstimulus intervals
500ms 700ms 900ms
Age-matched control;
N = 22 54.1 ±4.24 9 .8 ±2.34 2 .9 ±2.74 8 .0 ±2,1
PD patients with stage
1.5–2.0; N = 29
∗
31.1 ±6.6
∗∗
27.2 ±3.0
∗∗
18.0 ±3.3
∗∗
24.1 ±2,3
PD patients with stage
2.5–3.0; N = 29
∗
28.0 ±5.7
∗∗
23.9 ±5.4
∗∗
12.6 ±4.0
∗∗
19.3 ±3,1
All PD patients; N = 58
∗
29.8 ±4.8
∗∗
25.4 ±3.2
∗∗
15.1 ±2.6
∗∗
21,4 ±2,4
The inhibition was deﬁned: (A1 − A2)/A1∗100, where A1 is amplitude of the ﬁrst and A2 is amplitude of the second evoked potential upon paired-click
auditory stimulation. ∗P<. 01; ∗∗P<. 001 compared to control subjects (ANOVA, Mann-Whitney U test). N:-number of subjects in the investigated groups.
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Figure 2: Correlation of the averaged value of the paired-pulse
inhibition(evaluatedforISIsof500,700,and900ms)andageofthe
healthy age-matched subjects. rS is a coeﬃcient of nonparametric
Spearman rank-order correlation. N:-number of control subjects.
(P<. 001). No signiﬁcant relationship was observed between
the PPI value and the summary UPDRS score. Only negative
association (P<. 01) of the body bradykinesia score (point
31 of UPDRS) with the PPI value was observed. The scores
of the other UPDRS subitems had no signiﬁcant correlation
with the PPI value. Levodopa dosage and duration of the
Levodopa intake did not signiﬁcantly inﬂuence the brain
capacity for inhibition. We did not observe any signiﬁcant
correlation between the PPI value and sex, disease duration,
or Hoehn and Yahr stage (Table 3).
4. Discussion
The main result of this study showed that PD patients had
signiﬁcantly reduced PPI of the N1/P2 component of evoked
potentialsintheauditorycortexforISIs500,700,and900ms
comparedtothehealthyage-matchedsubjects.Thedegreeof
PPIcorrelatednegativelywithageofbothcontrolindividuals
Table 3: Correlation coeﬃcients between the averaged value of
the paired-pulse inhibition (PPI) and the characteristics of the PD
patients.
Characteristics of the PD patients
Averaged value of PPI
(%) in patients
(N = 58)
Age −0.29
∗
Sex 0.13
Disease duration −0.04
Age of the onset of the disease −0.28
∗
Hoehn and Yahr stage −0.15
Summary UPDRS score −0.14
Body bradykinesia score
(point 31 of UPDRS)
−0.35
∗∗
Duration of the levodopa intake 0.10 (N = 46)
Levodopa dosage 0.28 (N = 46)
Summary MMSE score 0.40
∗∗
Attention and memory score
(points 3 plus 4 of MMSE) 0.43
∗∗∗
Averaged value of PPI was evaluated for 500, 700, and 900ms interstimulus
intervals. N:-number of patients. Level of signiﬁcance: ∗ is P<. 05; ∗∗ is
P<. 01; ∗∗∗ is P<. 001 (nonparametric Spearman rank-order correlation).
and PD patients. In the group of PD patients, a positive
correlation of the PPI value with the MMSE cognitive scores
and a negative correlation with age of disease onset and body
bradykinesia scores of the patients were observed.
Our results of decreased inhibition in the auditory cortex
are consistent with the data on a reduced postexcitatory
inhibition in the motor cortex in the patients with PD [6, 8–
10, 12, 32, 33]. Decreased cortical inhibition is also in agree-
ment with the data on a reduced postexcitatory inhibition of
themidlatencyauditory(P49)andsomatosensory(P13-N18,
P24-N31, P44-N75) evoked responses to paired stimulation
in PD patients [22, 23]. These facts give us evidence that
deﬁcient inhibitory mechanisms may be speciﬁc not only for
cortical but also for subcortical structures in PD.Parkinson’s Disease 5
PPI is usually considered to reﬂect presynaptic changes
in transmitters release [13–15]. Inhibitory GABA-dependent
propertiesaregreatcontributortoPPI.Asalreadyestablished
[34], aﬀerent volleys after initial excitatory postsynaptic
potentials (EPSPs) result in inhibitory postsynaptic poten-
tials (IPSPs). A system of GABAergic interneurons, which
can be activated by direct and indirect stimulations, may
play the major role in the genesis of these IPSPs [34, 35].
The synaptic release of GABA is suggested to be mediated
by presynaptic GABA receptors of the B-type [18, 36, 37].
ThereisalsostrongevidencethatDAmayregulateinhibitory
transmission at the synapses between pyramidal cells and
interneurons by activating D1-like receptors located on the
presynaptic terminals of GABAergic axons [38, 39]. Calcium
and sodium channels are potential DA targets [40, 41]. It is
noteworthy that DA reveals regulation of both spontaneous
and evoked GABA release in cortical neurons [39, 42].
Another possible explanation of the reduced inhibition
in the auditory cortex in patients with PD may be the
loss of dopaminergic transmission in the basal ganglia
and the dysfunction of the caudal pallidum that sends its
directprojectionstotheinferiorcolliculus,medialgeniculate
nucleus, and temporal cerebral cortex [43]. The basal ganglia
appear to “gate” sensory inputs at various levels [44]a n d
activation of basal ganglia outputs (entopeduncular nucleus
and substantia nigra pars reticulate) is able to inhibit sensory
responses [45].
The decreased inhibition of the second cerebral evoked
response on paired or repetitive auditory and somatosensory
stimulations also was shown in some other neurological
and psychiatric diseases: in patients with Huntington’s
disease [46], with myoclonus [47], in schizophrenic subjects
[48], and in Down’s syndrome individuals [49]. Several
researches presented convincing data demonstrating associ-
ation between the deﬁcit in inhibitory capacity and cogni-
tive impairment [24, 50]. For example, in schizophrenics,
decreased level of attention correlated with the increased
ratio of the second to the ﬁrst amplitude of the P50 auditory
evokedresponseinapairedstimulus[50].Recentstudiesthat
used a prepulse inhibition paradigm revealed a signiﬁcant
reduction of inhibitory processes in the auditory cortex
in individuals suﬀering from PD dementia and dementia
with Lewy bodies [24]. A prepulse inhibition paradigm is
considered to reﬂect the state of attention control or ability
to ﬁlter out repeated irrelevant sensory information [51, 52].
In line with the above-mentioned studies, our data about
signiﬁcant positive correlation of the PPI value in auditory
cortex with summary MMSE score (rS = 0.40, P<. 01) and
attentionplusmemoryscoreofMMSE(rS = 0.43, P<. 001)
provide additional evidence that a deﬁcit of inhibition might
contribute to cognitive disturbances in PD patients.
In the present study, along with a correlation between
the degree of PPI and cognitive indices, we found a negative
associationofthebodybradykinesiascoresofthePDpatients
with PPI value (rS =− 0.35, P<. 01). This fact may
be interpreted as evidence of the essential participation
of the brain inhibitory processes in motor realizations
that need sensory guidance, such as rapidity, amplitude of
movements, and arm swings while walking (cheirokinesis).
Interestingly, a recent study which investigated possible
associations between cognitive status and six diﬀerent motor
activities (facial expression, tremor, rigidity, bradykinesia,
axial impairment, speech) found that only bradykinesia and
speech signiﬁcantly correlated with incident dementia in PD
patients [53].
Our investigation showed that the degree of PPI in the
auditory cortex correlated negatively with the age of both
control individuals and PD patients. Age-related decrease
in PPI was described earlier in motor cortex of healthy
subjects during paired-pulse transcranial magnetic stimula-
tion [54, 55]. Inhibitory processing deﬁcit related with age
was observed also in study of the cortical auditory evoked
potential N2 in two groups of young and elderly participants
[56]. Based on experimental researches, it is possible to
suppose that this age-dependent decline of inhibition is
due to a decrease of the density of GABAergic neurons
and alteration of the GABA-receptors composition in the
neocortex in aged subjects [57, 58]. Some researchers suggest
that the age-related deﬁcit of inhibitory function results in
inability to suppress eﬀectively the irrelevant information
that causes cognitive impairment and deterioration in motor
performance with advancing age [59, 60].
Our data showed negative connection (rS =− 0.28, P<
.05) between the PPI value and the age of PD onset. Perhaps,
an important determinant of inhibitory dysfunction in PD is
the combined eﬀect of the natural aging process (senescence
of cerebrum) and neurodegenerative changes, characteristic
for this disease. Notably, several studies reported the rela-
tionship between the age of the disease onset and cognition,
namely, older age at disease onset was associated with more
marked cognitive decline in PD patients [61–63].
Recently, there have been a lot of discussions regard-
ing the inﬂuence of Levodopa-containing preparations on
cerebral functions. While one study proved the absence
of negative inﬂuence of Levodopa-therapy [63], another
revealed that Levodopa can worsen cerebral activity [64]. In
this study, we did not ﬁnd any signiﬁcant dependence of
PPI value on duration of the Levodopa intake and Levodopa
dosage.
Overall, this study demonstrated that: (i) the PPI in
response to paired auditory stimulation was signiﬁcantly
reduced in patients with PD compared to control subjects;
(ii) the value of PPI in the auditory cortex correlated
negatively with the age of both control individuals and PD
patients; (iii) the value of the brain inhibitory function
correlated positively with cognitive functions and negatively
with age of the disease onset and body bradykinesia scores
of the PD patients. We propose two possible mechanisms
for the reduced postexcitatory cortical inhibition in PD:
dopaminergic transmission deﬁciency in the basal ganglia
and functional impairment of GABAergic cortical interneu-
rons caused by lack of dopamine regulating inﬂuences
through the depletion of dopaminergic innervation in the
cerebral cortex. Our ﬁndings may suggest that preparations,
being the derivatives of GABA, can be useful in medication
of PD. Phenibut (Noofen) belongs to such preparations
and it is able to activate cerebral inhibitory GABAergic
system [65, 66]. Application of Noofen in complex therapy6 Parkinson’s Disease
of PD appeared eﬀective for the improvement of cognitive
functions, enhancement of emotional state, and increase of
social adaptation of the PD patients [67].
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